Role of Combination Antiplatelet and Anticoagulation T Cardiovascular Disease

Circulation

141, 1841-1854

DOI: 10.1161/circulationaha.120.046448

Citation Report

#	Article	IF	Citations
1	Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus. Circulation, 2020, 142, 2172-2188.	24.6	56
2	Aspirin and Low-Dose Rivaroxaban – The Dual Pathway Concept in Patients With Stable Atherosclerotic Disease: A Comprehensive Review. Expert Review of Cardiovascular Therapy, 2020, 18, 577-585.	2.7	3
3	Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents. Circulation, 2020, 142, 1425-1436.	24.6	175
4	Insulin-Treated Diabetes Mellitus: An Actionable Risk Factor and Marker After Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventions, 2020, 96, 309-310.	2.2	2
5	Molecular Drivers of Platelet Activation: Unraveling Novel Targets for Anti-Thrombotic and Anti-Thrombo-Inflammatory Therapy. International Journal of Molecular Sciences, 2020, 21, 7906.	5.9	39
6	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. Circulation, 2020, 142, 1579-1590.	24.6	55
7	Rivaroxaban: A Review for Secondary CV Prevention in CAD and PAD. Drugs, 2020, 80, 1465-1475.	15.5	13
8	Highlights From the First Ever Virtual American College of Cardiology World Congress of Cardiology 2020 (ACC.20/WCC). Cardiovascular Research, 2020, 116, e75-e77.	13.5	0
9	Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease. Circulation, 2020, 141, 1855-1858.	24.6	2
10	Predicting 10-Year Risk of Recurrent Cardiovascular Events Andcardiovascular Interventions in Patients With Established Cardiovascular Disease: Results From UCC-SMART and REACH. International Journal of Cardiology, 2021, 325, 140-148.	3.2	23
11	Use of Risk Scores to Identify Lower and Higher Risk Subsets Among COMPASS-Eligible Patients With Chronic Coronary Syndromes. Insights From the CLARIFY Registry. Clinical Cardiology, 2021, 44, 58-65.	3.1	1
12	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care, 2021, 44, S125-S150.	20.9	475
13	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	2.4	5
14	The Association Between Platelet Indices and Cardiovascular Events in Chronic Kidney Disease Patients Without Dialysis. International Urology and Nephrology, 2021, 53, 961-971.	2.3	16
15	Selección de lo mejor del año 2020 sobre el tratamiento antitrombótico para el cardiólogo clínico. REC: CardioClinics, 2021, 56, 54-58.	0.3	0
16	Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 11, 608247.	5.3	9
17	Plasma Fibrin Clot Properties and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Long-Term Follow-Up Study. Cardiovascular Diabetology, 2021, 20, 1-11.	15.7	14
18	Antithrombotic Therapy in Diabetes: Which, When, and for How Long?. European Heart Journal, 2021, 42, 2235-2259.	14.7	61

#	Article	IF	Citations
19	Diabetes Mellitus Is Not Associated With Enhanced Bleeding Risk in Patients After Percutaneous Coronary Intervention. Diabetic Medicine, 2021, 38, e14532.	3.4	3
20	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Italy. Clinical Drug Investigation, 2021, 41, 459-468.	3.1	12
21	Life and Limb Protection With Dual Anti-Thrombotic Pathway Inhibition: COMPASS Ushers in a New Day in Atherothrombotic Risk Reduction. Med, 2021, 2, 233-242.	12.3	4
22	Prevalence of Diabetes and Impact on Cardiovascular Events and Mortality in Patients With Chronic Coronary Syndromes, Across Multiple Geographical Regions and Ethnicities. European Journal of Preventive Cardiology, 2022, 28, 1795-1806.	6.1	37
23	Benefits of Ticagrelor Plus Aspirin According to Diabetes-Related Factors: A Complex Equation. Journal of the American College of Cardiology, 2021, 77, 2378-2381.	12.0	1
24	Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The Role of the COMPASS Strategy. Current Cardiology Reviews, 2021, 17, 294-305.	2.9	4
25	Current State-of-the-Art Antiplatelet and Anticoagulation Therapy in Diabetic Patients With Coronary Artery Disease. Future Cardiology, 2021, 17, 521-534.	1.2	4
26	Diabetes-Related Factors and the Effects of Ticagrelor Plus Aspirin in the THEMIS and THEMIS-PCI Trials. Journal of the American College of Cardiology, 2021, 77, 2366-2377.	12.0	20
27	Cardiovascular Risk Management in Type 2 Diabetes Mellitus: A Joint Position Paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	4.0	5
28	Therapie bei asymptomatischer Stenose der extrakraniellen A. carotis. Deutsche Medizinische Wochenschrift, 2021, 146, 793-800.	0.3	1
29	Heterogeneity Amongst GLP-1 RA Cardiovascular Outcome Trials Results: Can Definition of Established Cardiovascular Disease Be the Missing Link?. Diabetology and Metabolic Syndrome, 2021, 13, 1-13.	5.2	12
30	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. Circulation, 2021, 144, 74-84.	24.6	74
31	Kidney, Limb and Ophthalmic Complications, and Death in Patients With Nonvalvular Atrial Fibrillation and Type 2 Diabetes Prescribed Rivaroxaban or Warfarin: An Electronic Health Record Analysis. Current Medical Research and Opinion, 2021, 37, 1493-1500.	2.9	6
32	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	12.0	52
33	Antithrombotic Therapies in Aortic and Peripheral Arterial Diseases in 2021: A Consensus Document From the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Thrombosis, and the ESC Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2021, 42, 4013-4024.	14.7	135
34	Antithrombotic Treatment for Peripheral Arterial Occlusive Disease. Deutsches Ärzteblatt International, 2021, 118, 528-535.	3.5	7
35	Phase I Clinical Trial of an Antithrombotic Drug Protocol Combining Apixaban and Clopidogrel in Dogs. Journal of Veterinary Cardiology, 2021, 36, 105-114.	1.6	8
36	Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clinical Diabetes, 2021, 39, 358-388.	4.0	4

#	Article	IF	Citations
37	Rivaroxaban Compared With Low-Dose Aspirin in Individuals With Type 2 Diabetes and High Cardiovascular Risk: A Randomised Trial to Assess Effects on Endothelial Function, Platelet Activation and Vascular Biomarkers. Diabetologia, 2021, 64, 2701-2712.	9.8	22
38	Hypofibrinolysis in Type 2 Diabetes and Its Clinical Implications: From Mechanisms to Pharmacological Modulation. Cardiovascular Diabetology, 2021, 20, 1-16.	15.7	59
39	Role of Diabetes in Stroke: Recent Advances in Pathophysiology and Clinical Management. Diabetes/Metabolism Research and Reviews, 2022, 38, e3495.	8.4	39
40	Prevalence, Prescriptions, Outcomes and Costs of Type 2 Diabetes Patients With or Without Prior Coronary Artery Disease or Stroke: A Longitudinal 5-Year Claims-Data Analysis of Over 7 Million Inhabitants. Therapeutic Advances in Chronic Disease, 2021, 12, 20406223211026390.	3.1	9
41	Diabetes Mellitus and Outcomes of Lower Extremity Revascularization for Peripheral Artery Disease. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 298-306.	4.9	21
42	Generalizability of Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial in Patients With a History of Coronary Artery Bypass Graft Surgery. Current Opinion in Cardiology, 2021, 36, 172.	2.2	12
43	Prolonged Antithrombotic Therapy in Patients After Acute Coronary Syndrome: A Critical Appraisal of Current European Society of Cardiology Guidelines. Cardiology Journal, 2020, 27, 661-676.	1.7	11
44	Clinical Outcome Between Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndrome and Diabetes. Cardiovascular Therapeutics, 2021, 2021, 5546260.	3.0	8
45	Prevalence and Clinical Implications of Eligibility Criteria for Prolonged Dual Antithrombotic Therapy in Patients With PEGASUS and COMPASS Phenotypes: Insights From the START-ANTIPLATELET Registry. International Journal of Cardiology, 2021, 345, 7-13.	3.2	47
46	Concomitant Diabetes With Atrial Fibrillation and Anticoagulation Management Considerations. European Heart Journal Supplements, 2020, 22, O78-O86.	2.9	20
47	Новые возможности снижения резидуального риска при ишемической болезни сердца. Kardiologiya, 2020, 60, 110–116.	0.9	7
48	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	16
49	Direct Oral Anticoagulants Combined With Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-Analysis. Drugs, 2021, 81, 2003-2016.	15.5	7
50	Optimum Treatment Strategy in Chronic Coronary Syndromes: The New Trials vs the Current Guidelines. Rational Pharmacotherapy in Cardiology, 2021, 17, 761-770.	0.6	0
51	Современные возможности антитромботической терапии у пациентов с ишемической болезнью сердца и сахарным диабетом. Russian Journal of Cardiology, 2020, 25, 4077.	1.9	0
52	Low-Dose DOAK/ASS: Überzeugend bei hohem Risiko und Diabetes. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2020, 07, 282-283.	0.0	0
53	Dual Pathway Inhibition in Atherothrombosis Prevention: Yes, Now We Can!. Minerva Cardiology and Angiology, 2023, 71, 363-373.	1.3	2
54	The Year in Cardiovascular Medicine 2021: Diabetes and Metabolic Disorders. European Heart Journal, 2022, 43, 263-270.	14.7	10

#	Article	IF	Citations
55	Antiplatelet and Antithrombotic Therapy in Type I Diabetes Mellitus: Update on Current Data. Current Diabetes Reviews, 2022, 18, 16-24.	3.0	1
56	Current Management and Screening of Peripheral and Coronary Artery Disease in People With Diabetes Mellitus in Europe. The PADDIA/CADDIA Survey. Diabetes Research and Clinical Practice, 2022, 184, 109214.	4.1	8
57	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care, 2022, 45, S144-S174.	20.9	500
58	Diagnosis and Treatment of Acute Coronary Syndromes: A Review. JAMA - Journal of the American Medical Association, 2022, 327, 662-675.	37.0	769
59	Decrements in Health-Related Quality of Life Associated With Adverse Events in People With Diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 530-538.	6.0	24
60	KDM3A Inhibition Ameliorates Hyperglycemia-Mediated Myocardial Injury by Epigenetic Modulation of Nuclear Factor Kappa-B/P65. Frontiers in Cardiovascular Medicine, 2022, 9, 870999.	3.2	13
61	Пути оптимизации лечения пациентов с различными формами ишемической болезни сердца. Meditsinskiy Sovet, 2022, 0, 273-279.	0.4	1
62	Clinical Experience With Dual Pathway Inhibition Therapy: Case Series and Mini Review. European Heart Journal - Case Reports, 2022, 6, ytac201.	0.6	1
63	Periphere arterielle Verschlusskrankheit bei Menschen mit Diabetes. Die Diabetologie, 2022, 18, 549-560.	0.1	0
64	Outcomes of Hospitalized Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) With and Without a History of Peripheral Artery Disease. Cureus, 2022, 14, e26585.	1.3	0
65	Managing Thrombotic Risk in Patients With Diabetes. Cardiovascular Diabetology, 2022, 21, 1-16.	15.7	19
66	EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?. International Journal of Molecular Sciences, 2022, 23, 10120.	5.9	4
67	Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials. International Journal of General Medicine, 2022, 15, 7201-7208.	2.5	8
68	Antithrombotic Strategy in Secondary Prevention for High-Risk Patients With Previous Acute Coronary Syndrome: Overlap Between the PEGASUS Eligibility and the COMPASS Eligibility in a Large Multicenter Registry. American Journal of Cardiovascular Drugs, 2023, 23, 77-87.	3.7	4
69	Anticoagulants: A Short History, Their Mechanism of Action, Pharmacology, and Indications. Cells, 2022, 11, 3214.	6.4	147
70	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023. Diabetes Care, 2023, 46, S158-S190.	20.9	464
71	Diabetic Foot Ulcer: Challenges and Future. World Journal of Diabetes, 2022, 13, 1014-1034.	4.4	145
72	On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DES. Journal of the American Heart Association, 2023, 12, e026482.	5.8	13

#	Article	IF	Citations
73	Сахарный диабет 2 типа и микрососудистые осложнения у больных стабильной ишемической болезнью сердца: распространенность, прогноз и выбор антитромботической терапии. Ûžno-Rossijskij žurnal Terapevtičeskoj Praktiki, 2022, 3, 7-24.	0.3	4
74	Serum Platelet Distribution Width Predicts Cardiovascular and All-Cause Mortality in Patients Undergoing Peritoneal Dialysis. Postgraduate Medicine, 2023, 135, 394-401.	3.0	4
75	Rivaroxabana em Pacientes Ambulatoriais com COVID-19 Leve ou Moderada: Fundamentação e Desenho do Estudo CARE (CARE – Coalition COVID-19 Brazil VIII). Arquivos Brasileiros De Cardiologia, 2023, 120, e20220431.	1.2	2
76	Ischemia of Lower Limbs in the Activity of a General Practitioner — Family Physician: From Widely Spread to Rare Disorders (Literature Review With Some Results of the Own Clinical Observations). Emergency Medicine, 2023, 19, 21-31.	0.4	2
77	Low Dose Rivaroxaban for the Management of Atherosclerotic Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2023, 56, 91-102.	2.2	9
78	Low-Dose Rivaroxaban: Can Cardiovascular Events Be Reduced?. European Heart Journal Supplements, 2023, 25, C20-C26.	2.9	4
79	Diabetes and Cardiovascular Disease. Contemporary Cardiology, 2023, .	0.0	41
80	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2023, 82, 833-955.	12.0	620
81	Cardiovascular Effects of Rivaroxaban in Heart Failure Patients With Sinus Rhythm and Coronary Disease With and Without Diabetes: A Retrospective International Cohort Study From COMMANDER-HF. BMJ Open, 2023, 13, e068865.	2.7	2
82	Polydopamine-Mediated Immunomodulatory Patch for Diabetic Periodontal Tissue Regeneration Assisted by Metformin-ZIF System. ACS Nano, 2023, 17, 16573-16586.	16.8	115
83	2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients With Diabetes: Developed by the Task Force on the Management of Cardiovascular Disease in Patients With Diabetes of the European Society of Cardiology (ESC). European Heart Journal, 2023, 44, 4043-4140.	14.7	1,622
84	2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation, 2023, 148, e9-e119.	24.6	1,601
85	Cardiometabolic Guidelines: Cardiovascular Risk Assessment and Management in Patients With Dysglycemia. Dubai Diabetes and Endocrinology Journal, 2023, 29, 67-88.	1.0	9
86	Common Mechanisms Underlying Diabetic Vascular Complications: Focus on the Interaction of Metabolic Disorders, Immuno-Inflammation, and Endothelial Dysfunction. Cell Communication and Signaling, 2023, 21, 1-18.	11.7	139
87	Efficiency and Safety of Dual Pathway Inhibition for the Prevention of Femoropopliteal Artery Restenosis in Repeated Endovascular Interventions. Journal of Vascular Surgery, 2024, 79, 623-631.e2.	3.4	1
88	Von Willebrand Factor Hyperactivity Affects the Outcome of Lower Limb Revascularization in Subjects With Type 2 Diabetes Mellitus Complicated by Diabetic Foot Vasculopathy: An Observational Pilot Study. Journal of Diabetes and Its Complications, 2024, 38, 108653.	3.4	2
89	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care, 2024, 47, S179-S218.	20.9	547
90	Multifunctional Nanoparticle-Mediated Combining Therapy for Human Diseases. Signal Transduction and Targeted Therapy, 2024, 9, 1-33.	69.0	910

#	Article	IF	Citations
91	Primordial Drivers of Diabetes Heart Disease: Comprehensive Insights Into Insulin Resistance. Diabetes and Metabolism Journal, 2024, 48, 19-36.	6.9	55
92	Advances in Secondary Prevention Mechanisms of Macrovascular Complications in Type 2 Diabetes Mellitus Patients: A Comprehensive Review. European Journal of Medical Research, 2024, 29, 1-34.	5.0	42
93	Chinese Expert Consensus on Anti-Thrombotic Therapy for Pan-Vascular Diseases (2023 Edition). Cardiology Plus, 2024, 9, 49.	1.7	10
94	A Bayesian Approach Based on Discounting Factor for Consistency Assessment in Multi-Regional Clinical Trial. Journal of Biopharmaceutical Statistics, 2025, 35, 356-372.	1.5	0
95	Limb Outcomes With Ticagrelor Plus Aspirin in Patients With Diabetes Mellitus and Atherosclerosis. Journal of the American College of Cardiology, 2024, 83, 1627-1636.	12.0	12
96	The ABCs of the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease. Clinical Cardiology, 2024, 47, e24284.	3.1	14
97	Impact of Frailty on the Benefits of Dual Pathway Inhibition for the Secondary Prevention of Cardiovascular Events in the COMPASS Randomised Trial. Canadian Journal of Cardiology, 2025, 0, 102-111.	3.8	7
98	Does Benefits of Rivaroxaban as Add-On to Aspirin Apply to Diabetes-Related Cardiovascular Disease? Insights From the COMPASS and VOYAGER PAD Trials. International Journal of Diabetes in Developing Countries, 2024, 44, 768-770.	1.0	0
99	Cardiovascular Risk Reduction in Type 2 Diabetes: What the Non-Specialist Needs to Know About Current Guidelines. Diabetes, Obesity and Metabolism, 2024, 26 Suppl 5, 14-24.	6.0	15
100	2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2024, 48, 546-708.	6.9	76
101	Diabetes and Stroke—A Focused Review. Journal of Diabetology, 2024, 15, 247.	0.5	5
102	Periphere Arterielle Verschlusskrankheit Bei Diabetes Mellitus. Aktuelle Kardiologie, 2024, 13, 277-283.	0.0	0
103	Chronic Coronary Syndromes: Diagnosis, Management and Gaps in Evidence. Heart Vessels and Transplantation, 2024, 8, 391.	0.1	3
104	The Role and Mechanism of Vascular Aging in Geriatric Vascular Diseases. Aging and disease, 2024, 16, 2237-2249.	7.1	14
105	Cardiometabolic Diseases—Recent Advance in Antithrombotic and Thrombolytic Therapies. , 2025, .		1
106	Guía de práctica clínica sobre detección y manejo de la enfermedad renal diabética: documento de consenso de la Sociedad Española de Nefrología. Nefrologia, 2025, 45, 1-26.	0.6	5
107	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care, 2025, 48, S207-S238.	20.9	322
108	Unravelling the Cardio-Renal-Metabolic-Foot Connection in People With Diabetes-Related Foot Ulceration: A Narrative Review. Cardiovascular Diabetology, 2024, 23, 1-18.	15.7	37

#	Article	IF	Citations
109	A Saudi Heart Association Position Statement on Cardiovascular Diseases and Diabetes Mellitus. Journal of the Saudi Heart Association, 2024, 36, 385-407.	1.5	9
110	Emirates Consensus Recommendations on Cardiovascular Risk Management in Type 2 Diabetes. Frontiers in Endocrinology, 2025, 15, 1395630.	5.8	3
111	Влияние антитромботической терапии на факторы риска развития сердечно-сосудистых осложнений у пациентов с ишемической болезнью сердца и сахарным диабетом. Акцент на гиперкоагуляцию. Kardiologiya, 2024, 64, 86-95.	0.9	0
112	Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review. Expert Opinion on Drug Safety, 2025, 24, 261-271.	3.2	7
113	Efficacy and Safety of Dual Antiplatelet Treatment Up to 72 Hours in Acute Ischemic Stroke Stratified by Glycemic Status. Annals of Neurology, 2025, 98, 174-182.	8.1	6
114	Correlation Between Blood Coagulation Profile and Viscosity: Clinical Laboratory Observational Study. Medical Sciences, 2025, 13, 20.	6.3	4
115	Role of Dual Pathway Inhibition in Secondary Prevention of Coronary Artery Disease. Cureus, 2025, 17, e80504.	1.3	0
116	Diabetic Status and Thrombogenicity: Association and Prognostic Implications After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2025, 18, 720-733.	5.0	7
117	Combined Use of Anti-Platelet Aggregation Drugs and Shujin Huoluo Decoction for Diabetic Peripheral Vascular Disease: Enhanced Therapeutic Efficacy. American Journal of Translational Research (discontinued), 2025, 17, 1756-1767.	1.5	0
118	Clinical Practice Guideline for Detection and Management of Diabetic Kidney Disease: A Consensus Report by the Spanish Society of Nephrology. Nefrologia, 2025, 45, 1-26.	1.3	6
119	Short-Term Effects of Rivaroxaban Combined With Aspirin in the Treatment of Lower Limb Arterial Atherosclerosis Occlusion With Stent Placement: A Retrospective Study. Medicine (United States), 2025, 104, e42147.	2.1	0
120	Explore Potential Immune-Related Targets of Leeches in the Treatment of Type 2 Diabetes Based on Network Pharmacology and Machine Learning. Frontiers in Genetics, 2025, 16, 1554622.	3.2	4
121	Strategies for the Secondary Prevention of Atherosclerotic Cardiovascular Disease. US Cardiology Review, 2025, 19, e11.	2.3	7
122	Effects of Low-Dose Rivaroxaban Combined With Low-Dose Aspirin Versus Low-Dose Aspirin Alone on in Vivo Platelet Activation, Endothelial Function and Inflammation in Type 2 Diabetes Patients With Stable Atherosclerotic Disease: The RivAsa Randomized, Crossover Study. Diabetes Research and Clinical Practice, 2025, 224, 112244.	4.1	4
123	Taurine Ameliorates Blood Pressure and Vascular Function in Patients With Type 2 Diabetes: Randomized, Double-Blind, Placebo-Controlled Trial. IScience, 2025, 28, 112719.	4.5	7
124	Extended Dual Antithrombotic Therapy in Patients With Chronic Coronary Syndrome - Which Agent Should Be Added to Aspirin?. Cardiology Journal, 2025, 32, 321-327.	1.7	1
125	Expert Recommendations on Antithrombotic Management of Peripheral Artery Disease: Perspectives From Indian Interventional Radiologists. Journal of Clinical Interventional Radiology ISVIR, 2025, 09, 108-120.	0.3	0
126	2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2025, 49, 582-783.	6.9	53

#	Article	IF	Citations
127	Hydrogen Sulfide Replenishment Ameliorates Impaired Platelet Response to Clopidogrel in Mice With Experimental Diabetes Mellitus. Xenobiotica, 2025, 55, 488-498.	1.6	0
128	Sulforaphane Attenuates Aldose Reductase-Mediated Platelet Dysfunction in High Glucose-Stimulated Human Platelets via Downregulation of the Src/ROS/p53 Signaling Pathway. Frontiers in Nutrition, 2025, 12, 1663245.	5.6	3
129	Dual Pathway Inhibition Versus Antiplatelet Therapy for "Symptomatic" Lower-Extremities Peripheral Artery Disease in Diabetes Mellitus: A Systematic Review and a Meta-Analysis of Randomized Controlled Trials for the Development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome. Acta Diabetologica, 2026, 63, 1-13.	3.8	0
130	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	0
131	Platelets Impair the Resolution of Inflammation in Atherosclerotic Plaques in Insulin-Resistant Mice After Lipid Lowering. JCI Insight, 2025, .	6.8	3
132	Platelets and Diabetes. , 2025, .		0
133	Stratifying Cardiovascular Benefits From GLP-1RA: A Multisource Analysis of Patient-Level CVOT and Real-World Data Using AI-Driven Methods. Cardiovascular Diabetology, 2025, 24, 1-11.	15.7	2
134	Versatile Smart Hydrogels for Spatiotemporal Drug Delivery to Orchestrate Diabetic Bone Regeneration. Bioactive Materials, 2026, 55, 754-776.	23.4	18
135	Practical Guidelines for the Prevention and Management of Diabetic Foot Disease in China. Burns and Trauma, 2025, 13, tkaf064.	10.2	10
136	Cardiovascular Disease and Risk Management. , 2025, .		0
137	The Role of Rivaroxaban in the Management of Coronary Artery Disease: An Overview of Five Landmark Clinical Trials. Naunyn-Schmiedeberg's Archives of Pharmacology, 2026, 399, 1-11.	4.7	0
138	Relationship Between High Platelet Reactivity With Prasugrel and Clinical Events After Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: A PENDULUM Registry Substudy. Journal of Cardiology, 2026, 87, 406-413.	3.8	1
139	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care, 2026, 49, S216-S245.	20.9	152
140	Peripheral Artery Disease in Persons With Type 2 Diabetes. , 2026, .		0
141	Characteristics and Outcomes of Patients With Diabetes Mellitus Selected for Dual Pathway Inhibition in Clinical Practice: The XATOA Registry. Vascular Medicine, 2026, 31, 493-504.	2.3	0
142	Вибір терапевтичної стратегії для пацієнтів із високим ризиком повторних серцево-судинних подій. Ukrainian Medical Journal, 2026, .	0.1	0
143	An Overview of the Role of Platelets in Vascular Disease Associated With Diabetes Mellitus. Hormones, 2026, .	2.5	1
144	Targeting the AGE-RAGE System as a Therapeutic Approach for Endotheliopathy. Comparative Clinical Pathology, 2026, 35, 37.	1.0	1

#	Article	IF	Citations
145	Efficacy of Argatroban Plus Alteplase Versus Intravenous Alteplase According to Diabetes Mellitus in Acute Ischemic Stroke. Scientific Reports, 2026, 16, 15963.	5.2	0
146	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❄SAIMSARA. , 2026, .		0
147	Diabetes Mellitus and Early Antiplatelet Treatment for Minor Stroke Following Intravenous Thrombolysis: Prespecified Secondary Analysis of the EAST Trial. Diabetes, Obesity and Metabolism, 2026, 28, 5604-5613.	6.0	0
148	Artériopathie des membres inférieurs chez le patient vivant avec un diabète de type 2 : marqueurs du risque et impact des thérapeutiques. , 0, .		0
149	Routine Haematological Parameters Associated With HbA1c and Estimated Whole-Blood Viscosity in Diabetes Management: An Exploratory AIC-Based Regression Analysis. Journal of Clinical Medicine, 2026, 15, 4995.	3.8	1
150	Interim Efficacy Analysis of Different Anticoagulation Regimens in Patients With Long-Term Implantation of Inferior Vena Cava Filter. Seminars in Thrombosis and Hemostasis, 2026, .	4.1	0
151	Meta-Analysis of the Effect of Self-Management Behavior Intervention Measures in Older Adults With Coronary Heart Disease and Diabetes Mellitus. Frontiers in Cardiovascular Medicine, 2026, 13, 1821784.	3.2	0
152	Edoxaban Antithrombotic Therapy in Diabetic Patients With Atrial Fibrillation and Stable Coronary Artery Disease: The EPIC-CAD Trial. Europace, 2026, .	8.4	0